# In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy

> **NCT07653438** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 20 (estimated)

## Conditions studied

- Stage III Non-small Cell Lung Cancer
- Unresectable Stage III NSCLC

## Interventions

- **DRUG:** Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT

## Key facts

- **NCT ID:** NCT07653438
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653438, "In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*